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Abstract
Background: Meningococcal factor H binding protein (fHbp) is a promising vaccine candidate. Anti-fHbp antibodies can
bind to meningococci and elicit complement-mediated bactericidal activity directly. The antibodies also can block binding
of the human complement down-regulator, factor H (fH). Without bound fH, the organism would be expected to have
increased susceptibility to bacteriolysis. Here we describe bactericidal activity of two anti-fHbp mAbs with overlapping
epitopes in relation to their different effects on fH binding and bactericidal activity.
Methods and Principal Findings: Both mAbs recognized prevalent fHbp sequence variants in variant group 1. Using yeast
display and site-specific mutagenesis, binding of one of the mAbs (JAR 1, IgG3) to fHbp was eliminated by a single amino
acid substitution, R204A, and was decreased by K143A but not by R204H or D142A. The JAR 1 epitope overlapped that of
previously described mAb (mAb502, IgG2a) whose binding to fHbp was eliminated by R204A or R204H substitutions, and
was decreased by D142A but not by K143A. Although JAR 1 and mAb502 appeared to have overlapping epitopes, only JAR
1 inhibited binding of fH to fHbp and had human complement-mediated bactericidal activity. mAb502 enhanced fH binding
and lacked human complement-mediated bactericidal activity. To control for confounding effects of different mouse IgG
subclasses on complement activation, we created chimeric mAbs in which the mouse mAb502 or JAR 1 paratopes were
paired with human IgG1 constant regions. While both chimeric mAbs showed similar binding to fHbp, only JAR 1, which
inhibited fH binding, had human complement-mediated bactericidal activity.
Conclusions: The lack of human complement-mediated bactericidal activity by anti-fHbp mAb502 appeared to result from
an inability to inhibit binding of fH. These results underscore the importance of inhibition of fH binding for anti-fHbp mAb
bactericidal activity.
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Introduction
An effective vaccine against disease caused by capsular group B
strains of Neisseria meningitidis is not yet available (Reviewed in [1]).
The group B capsular polysaccharide, which consists of (2R8) N-
acetylneuraminic acid, is present in many human glycoproteins
[2,3]. This molecular mimicry results in the group B polysaccha-
ride being a poor immunogen [4]. Although controversial [5,6], a
vaccine that targets the group B capsule also may pose safety
concerns by eliciting auto-reactive antibodies. Efforts, therefore, to
develop group B meningococcal vaccines have focused largely on
non-capsular antigens [1,7].
One of the most promising non-capsular vaccine candidates is
factor H binding protein (fHbp), which previously was referred to
as GNA 1870 [8] or LP2086 [9]. fHbp is a surface-exposed
lipoprotein that binds the human complement protein, factor H
(fH). Bound fH down-regulates complement activation (particu-
larly by the alternative pathway) and enhances the ability of the
bacteria to survive in human serum [10–12] and cause invasive
disease [13,14]. fHbp is part of three vaccines in clinical
development. One vaccine includes three recombinant proteins
(five antigens), which are combined with detergent-treated outer
membrane vesicles [15,16]. The second contains two recombinant
fHbp sequence variants from different variant groups [17]. The
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mutant meningococcal strains with genetically attenuated endo-
toxin and over-expressed fHbp [18].
Based on amino acid sequence variability, fHbp has been
divided into three variant groups by Masignani et al [19], or two
sub-families, designed ‘‘A’’ and ‘‘B’’ by Fletcher et al [9]. Sub-
family A includes variant groups 2 and 3, and sub-family B
includes variant group 1. The amino acid identity between the two
sub-families is approximately 65%. In general, anti-fHbp anti-
bodies elicit complement-bactericidal activity only against strains
with fHbp from the same sub-family as that of fHbp vaccine
antigen [9].
Recently, the molecular architecture of fHbp also was reported
to be modular with five variable segments, each flanked by
invariant sequences [20]. Each of the variable segments is derived
from one of two lineages, designated 1 or 2 (http://pubmlst.
org/perl/bigsdb/bigsdb.pl?db=pubmlst_neisseria_seqdef&page=
alleleQuery&locus=FHbp_peptide) (The lineages were originally
referred to as alpha and beta, respectively [20]). fHbp amino acid
sequence variants can contain all five variable segments derived
from one lineage, or have variable segments from different
lineages (natural chimeras). While ten modular groups have been
recognized [21], 99% of all sequence variants identified to date
can be categorized into six modular groups, designated I to VI.
Anti-fHbp mAbs can bind to meningococci and elicit
complement-mediated bactericidal activity directly [22]. A
number of factors have been found to influence susceptibility of
different strains to anti-fHbp bacteriolysis. These included the
amount of fHbp expressed by a strain [23–25], antigenic cross-
reactivity [9,26], and IgG antibody subclass [25]. In addition, anti-
fHbp antibodies that blocked binding of fH would be expected to
increase susceptibility of the organism to bacteriolysis [10,12].
Support for this hypothesis came from recent studies of three
chimeric human IgG1 mouse anti-fHbp mAbs, two of which
inhibited binding of fH to fHbp, and had bactericidal activity [27].
However, the different locations on the fHbp molecule of the
epitopes recognized by the three mAbs also may have contributed
to the differences in bactericidal activity.
In the present study we determined the critical residues involved
in the interaction between fHbp and a murine anti-fHbp mAb,
designated JAR 1 [22], whose epitope had not been defined. JAR
1 is of interest because the mAb inhibited binding of fH to fHbp,
and was bactericidal with human complement. Further, the JAR 1
epitope overlapped that of a previously described murine anti-
fHbp mAb, mAb502 [28], which did not block fH binding to fHbp
[27,29,30], and was bactericidal only with rabbit complement.
The data illustrated how subtle differences in fine antigenic
specificity that affect fH binding can drastically affect mAb
protective activity.
Results
Anti-fHbp mAb JAR 1 is specific for fHbp sequence
variants in group 1
As of January 2012, more than 500 unique fHbp amino acid
sequence variants had been uploaded into the public database at
http://pubmlst.org/neisseria/fHbp/. Each of these variants has
been given unique identification (ID) numbers. As described in the
Introduction section, fHbp sequence variants can be categorized
into three variant groups [19]. We therefore tested binding of JAR
1 with eighteen recombinant fHbp sequence variants. These were
selected to be representative of each of the three variant groups
(Table 1), and included examples of variants expressed by
prevalent disease-causing isolates [24,31]. By ELISA, JAR 1
bound to fHbp ID 1, which is in variant group 1, but did not bind
with fHbp ID 77 in variant group 2 or fHbp ID 28 in variant
group 3 (Figure 1, Panel A). The presence of fHbp ID 77 or ID 22
on the plate was confirmed by binding of a second anti-fHbp mAb,
JAR 13 (Panel B), which is specific for fHbp in variant groups 2
and 3 [26,32]. In experiments not shown, JAR 1 also did not bind
with two other fHbp sequence variants in variant group 2 (ID 19,
22), or four others in variant group 3 (ID 45, 67, 79, or 175).
We next tested binding of JAR 1 to nine other recombinant
fHbp amino acid sequences in variant group 1 (Figure 1, Panel C).
JAR 1 bound to ID 2, 4, 9 and 13 but not with ID 6, 14, 15, 55 or
74. The presence of each of the recombinant protein sequence
variants on the plate was confirmed by binding of JAR 65 (Panel
D), which is a broadly reactive anti-fHbp mAb from a mouse
immunized with fHbp ID 1 (Table 1). Thus, including fHbp ID 1,
JAR 1 bound to five of the 10 sequence variants tested from
variant group 1.
The relatedness of each of the 10 sequence variants in group 1
was determined by a network analysis as generated by the
program, SplitsTree [33] (Figure 2). The sequence variants that
bound JAR 1 clustered together and were distinct from those that
did not bind JAR 1. Interestingly, with one exception, the
reactivity of JAR 1 with the different sequence variants paralleled
that of a previously described murine IgG2a anti-fHbp mAb,
mAb502 [28,29] (data not shown). The exception was fHbp ID 2,
which was positive for binding with JAR 1 but negative for binding
with mAb502 (see below).
Anti-fHbp JAR 1 recognizes an overlapping epitope with
mAb502
To investigate the possibility that JAR 1 and mAb502 had
overlapping epitopes, we measured the ability of each of the mAbs
to inhibit binding of the other to fHbp using a competitive
inhibition ELISA with fHbp ID 1 as the antigen adsorbed to the
wells. While JAR 1 inhibited binding of mAb502 to fHbp,
mAb502 did not inhibit binding of JAR 1 (Figure 3, Panel A).
To identify amino acid residues essential for JAR 1 binding, we
constructed a yeast library displaying randomly mutated fHbp ID
1 on the cell surface. Figure 3, Panel B shows an example of yeast
cells that were bound by both JAR 1 and a second positive control
anti-fHbp mAb JAR 5 [22,32], as measured by flow cytometry.
Yeast clones displaying fHbp mutants that were positive for JAR 5
binding but negative for JAR 1 binding were isolated by cell
sorting, expanded, and retested for binding. We determined the
DNA sequences encoding the mutant fHbp of 55 JAR 5-positive
and JAR 1-negative clones. Representative translated amino acid
sequences are shown in Figure S1. Based on the alignments, we
identified clones in which single amino acid mutations eliminated
JAR 1 binding. These residues included Asp at position 142
(D142), Lys at position 143 (K143), and Arg at position 204
(R204).
To determine whether the residues identified by the yeast
display studies affected JAR 1 epitope expression, we used site-
directed mutagenesis to replace each of the individual residues by
alanine, and tested the mutant recombinant proteins for binding
with JAR 1 by ELISA. All three mutants, and a fourth mutant,
R204H (see below) showed similar concentration-depending
binding with the positive control anti-fHbp mAb, JAR 5
(Figure 3, Panel C). For JAR 1 (Panel D), the D142A mutation
(blue squares) had no effect on binding, the K143A mutation (open
triangles) partially decreased binding, and the R204A mutation
(orange circles) resulted in complete loss of binding. We also
prepared a R204H mutant since we had shown that JAR 1 bound
to the natural fHbp sequence amino acid variant ID 2 (Figure 1,
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fHbp ID* Variant Group** Modular Group
" Source of Gene (Strain) References
1 1 I MC58 [19]
2 1 I Synthetic
{ [29]
4 1 I M4105 [22,24]
6 1 I M6190 [22,26]
9 1 I Mali 29/07 [24,40]
13 1 I M982 [9,48]
14 1 I NZ98/254 [22,48]
15 1 IV NM452 [21]
55 1 VI CDC-1573 [9]
74 1 VI Ug 10/06 [24,40]
19 2 VI MD01321 [49]
22 2 III RM1090 [26]
77 2 VI 8047 [26]
28 3 II M1239 [26]
45 3 V N27/00 [48]
67 3 VIII MA-5756 [50,51]
79 3 V S3032 [52]
175 3 IX synthetic
{{ [31]
*As designated in the fHbp public peptide database, http://pubmlst.org/neisseria/fHbp/.
**Variant groups as described by Masignani et al [19]. Proteins in variant group 1 are classified as ‘‘sub-family B’’ by Fletcher et al [9], and proteins in variant groups 2
and 3 are classified as ‘‘sub-family A’’. The relatedness of the amino acid sequences of fHbp in variant group 1 is illustrated in Figure 2.
"As described by Beernink and Granoff [20] and Pajon et al [21].
{codon usage was optimized for expression in E. coli based on the amino acid sequence obtained from the fHbp gene from strain M2197 [29].
{{codon usage was optimized for expression in E. coli based on the amino acid sequence obtained from the fHbp gene from strain 19498 (GenBank accession number
ACI46928) [31].
doi:10.1371/journal.pone.0034272.t001
Figure 1. Binding of anti-fHbp mAb JAR 1 to recombinant fHbp as measured by ELISA. Panel A. Binding of JAR 1 to fHbp ID 1 (variant
group 1); ID 77 (variant group 2); or ID 28 (variant group 3). Panel B. Binding of a control anti-fHbp, JAR 13, which is specific for fHbp in variant
groups 2 and 3 [32]. Sequence variants tested and respective symbols are those shown in Panel A. Panel C. Binding of JAR 1 to variants of fHbp in
variant group 1. ID 6, 14, 15, 55 and 74 are negative. ID 1, 2, 4, 9 and 13 are positive. Panel D. Binding of a positive control anti-fHbp mAb, JAR 65, to
recombinant fHbp variants shown in Panel C. Wells of the microtiter plates were coated with 2 mg/ml of each recombinant protein.
doi:10.1371/journal.pone.0034272.g001
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substitution of Ala for Arg at residue 204 eliminated binding of
JAR 1 to fHbp ID 1 (R204A), substitution of His for Arg at residue
204 of ID 1 did not affect JAR 1 binding (R204H, Figure 3, Panel
D).
In a previous study, mAb502 was shown to bind to an epitope
located in the C-terminal domain involving Arg204 [28,29]. In
our studies, both the R204A (orange circles, solid line) and R204H
mutations (magenta diamonds, dashed lines) in fHbp ID 1
eliminated mAb502 binding (Figure 3, Panel E). The lack of
binding of mAb502 to the R204H mutant was consistent with lack
of binding of this mAb to wild-type fHbp ID 2 that contains His at
residue 204 (green circles, Figure 3, Panel F). The D142A
mutation in fHbp ID 1, which had no effect on binding of JAR 1,
decreased binding of mAb502 (Panel E). Conversely, the K143A
mutation, which partially decreased binding of JAR 1, had no
effect on binding of mAb502. These results, together with the data
that JAR 1 inhibited binding of mAb502 to fHbp, indicated that
the two anti-fHbp mAbs recognized overlapping but distinct
epitopes.
JAR 1 and mAb502 differ in their ability to inhibit binding
of fH, and activate complement-mediated bacteriolysis
By ELISA, JAR 1 inhibited binding of fH to fHbp while
mAb502 did not inhibit fH binding. Indeed, mAb502 enhanced
fH binding to fHbp (Figure 4, Panel A). By flow cytometry,
mAb502 also did not inhibit binding of fH to the bacterial surfaces
of group B strain H44/76 (Panel B), or a mutant of group A strain
Senegal 1/99 with increased expression of fHbp ID 5 (Panel C).
For both strains there appeared to be a small but reproducible
increase in fH binding in the presence of mAb502. In contrast,
JAR 1 inhibited fH binding to both strains. The lower JAR 1
inhibition of fH binding with the group A strain likely reflected fH
bound by a second ligand, NspA [34], which has higher expression
in this test strain than in the group B H44/76 test strain.
In a bactericidal assay with human complement (Figure 4, Panel
D), JAR 1 and a positive control murine anti-PorA P1.7 mAb,
killed group B strain H44/76 while mAb502, which did not inhibit
fH binding, had no activity (200% survival of the bacteria after
1 hr incubation, which reflected an increase in the CFU compared
to time 0). In contrast, with infant rabbit complement, all three
mAbs had bactericidal activity (Figure 4, Panel E). Binding of fH
to N. meningitidis is specific for human fH [13]. Thus in the presence
of rabbit fH, which did not bind to the bacteria, mAb502 was
bactericidal.
Chimeric human IgG1 JAR 1 but not mAb502, is
bactericidal with human complement
The four mouse IgG subclasses have different complement
activation properties [35]. In order to investigate whether or not
the greater bactericidal activity of JAR 1 (IgG3) than mAb502
(IgG2a) resulted from different subclasses, we sequenced the
variable region genes encoding JAR 1 and created a chimeric
human IgG1 mouse JAR 1 mAb (See Methods). The activity of the
chimeric JAR 1 was compared to that of chimeric human IgG1
mAb502, which we had prepared in a previous study [27].
In an ELISA with recombinant fHbp ID 1 adsorbed to the wells
of a microtiter plate, the two human IgG1 chimeric mAbs showed
similar respective binding (Figure 5, Panel A). As observed with the
corresponding mouse mAbs, the chimeric JAR 1 mAb inhibited
binding of fH to fHbp, while the chimeric mAb502 mAb gave
slightly more fH binding (seen as negative inhibition, Figure 5,
Panel B). By flow cytometry, there also was slight enhancement of
fH binding to live bacterial cells of group B strain H44/76 by the
chimeric mAb502 (Figure 5, Panel C). In contrast, as little as 2 mg/
ml of the chimeric JAR 1, inhibited binding of fH to the surface.
With human complement, the chimeric human IgG1 JAR 1
mAb (red triangles) had bactericidal activity against strain H44/76
while the chimeric IgG1 mAb502 (green circles) was not
bactericidal (Figure 5, Panel D). The mouse anti-PorA P1.7
mAb (blue diamonds, dashed lines) had the strongest activity. With
rabbit complement, both anti-fHbp mAbs, and the control mouse
anti-PorA mAb, had bactericidal activity (Figure 5, Panel E).
Discussion
fHbp consists of two domains of antiparallel b-strands
connected by a five amino acid linker [36–38]. In previous
studies, our laboratory produced a panel of anti-fHbp mAbs from
mice immunized with fHbp sequence variants from each of the
three variant groups [22,32,39]. The majority of the mAbs
recognized epitopes located in either a conserved portion of the N-
terminal domain, or more variable regions in the C-terminal
domain of the protein [32,39]. In the present study, we have
characterized the functional properties of anti-fHbp mAb, JAR 1,
and the amino acid residues affecting the JAR 1 epitope, which
had not been defined. The results were compared to those of a
previously described anti-fHbp mAb, mAb502 [28,29].
Both JAR 1 and mAb502 bound to a subset of fHbp sequences
in variant group 1, which included ID 1, 4 and 9. In previous
studies, fHbp ID 1 was expressed by prevalent group B strains
responsible for meningococcal disease in the United States and
Europe [31]; and fHbp ID 9 was expressed by W-135 isolates
causing epidemic meningococcal disease in Africa [24,40].
Interestingly, fHbp ID 4 is associated both with group B strains
causing meningococcal disease in the UK [31], and group A
isolates causing epidemics in the Africa [24,40].
Based on previous studies, the epitope recognized by mAb502
was known to be located on the C-terminal domain of fHbp [29].
The mAb was bactericidal with rabbit complement [28], and did
not inhibit binding of human fH [29]. Data from the present study
suggested that JAR 1 and mAb502 recognized overlapping
epitopes. Thus, by ELISA, an excess of JAR 1 inhibited .90%
of binding of mAb502 to fHbp (Figure 3, Panel A); for reasons that
Figure 2. Network analysis of the relatedness of the fHbp
amino acid sequence variants tested for JAR 1 binding. The
network analysis was generated by the program, Splits Tree [33]. All
sequence variants were in variant group 1. Each variant is designated by
its peptide ID number as described in the public fHbp sequence variant
database (http://pubmlst.org/neisseria/fHbp/) followed by Roman
numeral I or IV, which designates the fHbp modular group [20,21].
Sequence variants represented by filled black circles were positive for
binding to JAR 1; sequence variants represented by open circles were
negative for binding to JAR 1 (See Figure 1).
doi:10.1371/journal.pone.0034272.g002
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mAb502 did not inhibit binding of JAR 1). The lack of mAb502
inhibition of JAR 1 binding did not appear to have resulted from
low mAb502 binding avidity since in a previous study mAb502
had high avidity measured by surface plasmon resonance (a rapid
association rate (ka) to immobilized fHbp, and a dissociation rate
that was too slow that the actual avidity constant couldn’t be
calculated [27]).
Binding of both JAR 1 and mAb502 to recombinant mutants of
fHbp was eliminated by a single amino acid substitution (Ala for
Arg at residue 204). While mAb502 binding also was eliminated by
substituting His for Arg204, this substitution did not affect JAR 1
binding. Binding of JAR 1, but not mAb502, to the natural fHbp
sequence variant ID 2, which has His at residue 204, was
consistent with the respective data with binding to the R204H
mutant from fHbp ID 1. Thus, Arg at position 204 appears to be
necessary for binding of mAb502, whereas another positively
charged residue, His, at this position is sufficient for binding of
JAR 1. The effects of these substitutions at 204 are likely to be
direct effects given the spatial proximity of other residues affecting
binding of the two mAbs (see below). Binding of JAR 1 also was
decreased by the K143A substitution but not by the D142A
substitution; the reverse was observed with mAb502 (binding was
decreased by the D142A substitution but not by the K143A
substitution). On a structural model, which shows the portion of
the fHbp molecule in contact with a fragment of fH, the Asp142
and Lys143 residues on fHbp are located in proximity to Arg204
on the C-terminal domain of fHbp (D142, K143 and R204,
respectively, Figure 6, Panels A and B). Interestingly, none of these
amino acid substitutions affected binding of fH to fHbp (Figure
S2). Small differences between the locations of the respective
epitopes recognized by JAR 1 and mAb502 in relation to the fHbp
residues known from the crystal structure to be in contact with fH,
and/or their respective orientations of mAb binding, may explain
the ability of JAR 1 but not mAb502 to inhibit fH binding.
Alternatively, binding of the mAbs may have induced different
Figure 3. Anti-fHbp mAbs JAR 1 and mAb502 recognize overlapping epitopes on the C-terminal domain of fHb. Panel A. Inhibition of
binding of a fixed concentration (1 mg/ml) of anti-fHbp mAbs to recombinant fHbp as measured by ELISA. Red triangles: inhibition of binding of
mAb502 (IgG2a) by JAR 1 (IgG3). Green circles: Inhibition of binding of JAR 1 by mAb502. Error bars represent ranges in independent assays. Panel B.
Binding of JAR 1 to yeast clones displaying randomly mutated fHbp on their surface. A representative clone is positive for binding to JAR 1 (red solid
line) and a control anti-fHbp mAb, JAR 5 (blue dashed line). Panels C, D, E. Binding of anti-fHbp mAbs to mutants of recombinant fHbp as measured
by ELISA. Crosses, wild-type (WT) fHbp ID 1; Blue squares, D142A mutant; White triangles, K143A mutant; Orange circles, R204A mutant; Pink
diamonds with dashed black line, R204H mutant. Panel C. Binding of JAR 5 (positive control, data are superimposed). Panel D. Binding of JAR 1.
Panel E. Binding of mAb502. Panel F. Binding of JAR 1 (red triangles with solid red line) or mAb502 (green circles with dashed line) to fHbp ID 2,
which has H204 instead of R204 in ID 1. Wells were coated with 2 mg/ml of wild-type or mutant fHbp.
doi:10.1371/journal.pone.0034272.g003
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decreased fH binding, and with mAb502 enhanced fH binding.
Distinguishing between these possibilities will require additional
study.
In a previous study, we showed that inhibition of fH binding
was essential for bactericidal activity of human IgG1 chimeric
mouse anti-fHbp mAbs [27]. Our conclusions, however, were
based on data from only two chimeric anti-fHbp mAbs that
blocked fH binding (JAR 3 and JAR 5) and chimeric mAb502,
which did not block fH binding. The fHbp epitopes recognized by
JAR 3 and JAR 5 required Gly121 and Lys122 while that of
mAb502 required Arg204. Thus, the different locations of the JAR
3 and JAR 5 epitopes and that of mAb502 confounded the analysis
of the role of fH inhibition on human IgG1 anti-fHbp mAb
bactericidal activity. In the present study, JAR 1 was shown to
recognize an epitope that overlapped that of mAb502. Since JAR
1 inhibited fH binding, and mAb502 did not inhibit fH binding, it
was possible to investigate the role of inhibition of fH binding on
human IgG1 mAb bactericidal activity independent of a large
difference in the locations of the two epitopes. The chimeric IgG1
JAR 1 elicited human complement-mediated bactericidal activity
against the wild-type group B strain H44/76, while the chimeric
IgG1 mAb502 was not bactericidal (Figure 5, Panel D). These
results were consistent with the importance of inhibition of binding
of fH for eliciting human IgG1 anti-fHbp mAb bactericidal
activity [27]. In our studies, binding of the mouse or chimeric
human mAb502 was shown to enhance binding of fH slightly to
both of the meningococcal test strains. Defining the mechanism for
fH enhancement, and the role of enhanced fH binding as opposed
simple lack of inhibition of fH binding, on resistance of N.
meningitidis to anti-fHbp mAb human complement-mediated killing
will require additional study.
The lack of cross-reactivity of most anti-fHbp mAbs against
strains expressing heterologous fHbp variants highlights an
important limitation of fHbp as a vaccine antigen, namely that
natural fHbp variants elicit little cross-protective antibody
responses against strains with fHbp from different sub-families or
variant groups [19,24,41]. Information on the locations of the
fHbp epitopes important for eliciting bactericidal antibodies have
enabled new vaccine strategies to engineer chimeric fHbps capable
of eliciting cross-reactive bactericidal antibodies against strains
expressing fHbp variants from different antigen groups [26,42].
The identification of regions of the fHbp molecule responsible for
eliciting antibodies such as JAR 1, which block fH binding and
activate human complement bactericidal activity, and ultimately
understanding the basis for the opposite effects of mAb502, which
recognizes an overlapping epitope, may aid further in the design of
optimal chimeric fHbp antigens.
Methods
Ethics statement
Anti-fHbp mAb, JAR 1, was prepared in a CD-1 mouse in strict
accordance with the recommendations in the Guide for the Care
and Use of Laboratory Animals of the National Institutes of
Health. The protocol was approved by the Children’s Hospital &
Research Center Oakland Institutional Animal Care and Use
Committee. The human complement source for measuring serum
bactericidal activity was serum from an adult who participated in a
protocol that was approved by the Children’s Hospital Oakland
Figure 4. Inhibition of binding of fH in relation to anti-fHbp mAb bactericidal activity. Panel A. Inhibition of fH binding to recombinant
fHbp as measured by ELISA. A fixed concentration of human fH (2 mg/ml) was incubated with different concentrations of anti-fHbp mAb JAR 1 (red
triangles with solid red line) or mAb502 (green circles with dashed green line). Panels B. Inhibition of fH binding to live bacteria of wild-type group B
strain H44/76 as measured by flow cytometry. A fixed concentration of fH (,90 mg/ml) was incubated with 2 mg/ml of JAR 1, or 2 or 50 mg/ml of
mAb502. The source of human fH was 20% IgG-depleted human serum. Dark gray filled area, bacteria without fH as a negative control; Light gray
filled area, fH without the addition of a mAb; fH and JAR 1 (red line); fH and mAb502, (green dashed line). Data for 2 or 50 mg/ml of mAb502 were
similar; only 50 mg/ml histogram is shown. Panel C. Inhibition of fH binding to live bacteria of a mutant of group A strain Senegal 1/99 with over-
expressed fHbp ID 5 as measured by flow cytometry. Symbols same as in Panel B. Panel D. Survival of N. meningitidis group B H44/76 strains after
60 min incubation with anti-fHbp mAbs and 20% human complement. JAR 1 (red triangles) and the anti-PorA P1.7 mAb control were bactericidal but
not mAb502 (green circles). Panel E. Same as Panel D except infant rabbit complement was used instead of human complement. All three mAbs had
activity. For each panel, the respective results were replicated in two independent experiments. Error bars represent ranges in values.
doi:10.1371/journal.pone.0034272.g004
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obtained from the subject.
Murine mAbs
The murine fHbp-specific monoclonal antibodies (mAbs) used
in this study are summarized in Table 2. All but one of the mAbs
have been previously described [22,28,29,32,39]. The exception,
JAR 65, was from a human fH transgenic BALB/c mouse
immunized with a mutant of recombinant fHbp ID 1 in which Arg
at position 41 was replaced by Ser (R41S), which eliminated fH
binding [43]. All of the mAbs listed in Table 1 elicited cooperative
human complement-mediated bactericidal activity in combination
with certain second anti-fHbp mAbs. In addition JAR 1, 5, 13, and
65 inhibited binding of fH to fHbp; mAb502 did not inhibit fH
binding. A control IgG2a anti-PorA P1.7 mAb was obtained from
the National Institute for Biological Standards and Control,
Potters Bar, United Kingdom (NIBSC code 01/514).
Chimeric human IgG1 mouse anti-fHbp mAbs
The methods for sequencing the variable region genes, vector
construction, transfection, antibody expression, and protein
purification of chimeric human IgG1 mouse anti-fHbp JAR 1
and mAb502 mAbs have been previously described [27].
Transfected CHO cells were cultured in serum-free medium
(Sigma Aldrich) for approximately 2 weeks. Antibody from the cell
culture supernatant was concentrated and purified using HiTrap
protein G columns (GE Healthcare) as described previously [27].
The concentrations of the human IgG-mouse chimeric mAbs were
determined by a capture ELISA in which a goat anti-human k
chain specific antibody (Biosource) was adsorbed to the wells of a
microtiter plate and used to capture the chimeric mAb. The
bound mAb was detected with goat anti-human k chain specific
antibody conjugated with alkaline phosphatase (Biosource). The
concentrations of the chimeric human mouse anti-fHbp mAbs
were assigned by comparison with binding of a human IgG1
myeloma standard (Sigma).
Anti-fHbp ELISA
Binding of the murine mAbs to recombinant fHbp (rfHbp) was
measured by ELISA as described previously [27]. The wells of a
microtiter plate (Immulon 2B; Thermo Electron Corp.) were
coated with 2 mg/ml of rfHbp in PBS and incubated overnight at
4uC. After blocking, different concentrations of the mAb were
added and incubated overnight at 4uC. The plates were washed
and bound mAb was detected with goat anti-mouse or anti-human
IgG (Fc specific)-alkaline phosphatase (Sigma; 1:5000).
The ability of the anti-fHbp mAbs to inhibit binding of fH to
fHbp also was measured by ELISA, which was performed as
previously described [27]. Briefly, wells of a microtiter plate were
incubated with rfHbp (2 mg/ml in PBS) overnight at 4uC.
Dilutions of the mAbs were added and incubated at 37uC for
2 hrs, followed by the addition of 2 mg/ml of purified human fH
(Complement Technology), which was incubated for an additional
1 hour at room temperature. Bound fH was detected by a sheep
polyclonal antiserum to fH (Abcam), followed by washing and the
addition of donkey anti-sheep IgG antibody (Sigma Aldrich)
conjugated with alkaline phosphatase. The inhibition results were
expressed as the percentage of inhibition of fH binding in the
presence of an anti-fHbp mAb, compared with fH binding in the
absence of the mAb.
Figure 5. Activity of chimeric human IgG1 mouse anti-fHbp mAbs. Panel A. Binding of chimeric mAbs to fHbp by ELISA using anti-human
kappa light chain secondary antibody (See Methods). Red triangles with solid red line, chimeric JAR 1; Green circles with dashed line, chimeric
mAb502. Panel B. Inhibition of fH binding to recombinant fHbp as measured by ELISA. Human fH (2 mg/ml) was incubated with different
concentrations of chimeric JAR 1 or chimeric mAb502. Symbols as in Panel A. Panel C. Inhibition of binding of fH to live bacteria of group B strain
H44/76 as measured by flow cytometry. A fixed concentration of human fH (,90 mg/ml) was incubated with 2 mg/ml of chimeric JAR 1, or 2 or 50 mg/
ml of chimeric mAb502. The source of fH was 20% IgG-depleted human serum. Dark gray filled area, bacteria without fH as a negative control; Light
gray filled area, fH without the addition of a mAb; fH and JAR 1 (solid red line); fH and mAb502 (green dashed line). Data for 2 or 50 mg/ml of chimeric
mAb502 were similar; only the 50 mg/ml histogram is shown. Panel D. Survival of wild-type group B strain H44/76 after 60 min incubation with
chimeric anti-fHbp mAbs and 20% human complement. Symbols for chimeric anti-fHbp mAbs are same as in Panel A; Blue diamonds with dashed
blue line, positive control anti-PorA P1.7 mAb. Data are from two experiments. Error bars, range in values. Panel E. Same as Panel D except that
infant rabbit complement was used instead of human complement.
doi:10.1371/journal.pone.0034272.g005
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The ability of anti-fHbp mAb JAR 1 (IgG3) to inhibit binding of
anti-fHbp mAb502 (IgG2a), or of mAb502 to inhibit binding of
JAR 1, to solid-phase recombinant fHbp was performed as
described elsewhere [44]. In brief, wells of a microtiter plate were
coated with 2 mg/ml of rfHbp and incubated overnight at 4uC.
Dilutions of the first mAb were added to the plate together with a
fixed concentration (1 mg/ml) of the second mAb and incubated at
37uC for 2 hrs. The secondary antibodies for detection of JAR 1 or
mAb502 were alkaline phosphatase-conjugated goat anti-mouse
antiserum specific for IgG3 or IgG2a, respectively (Southern
Biotech; 1:2000).
Flow cytometry
The ability of the mAbs to inhibit binding of fH to live bacteria
was measured by flow cytometry, which was performed as
described previously [27]. The group B test strain was H44/76
(B:15:P1.7,16; ST-32), which expressed fHbp ID 1 in variant
group 1 [22,23]. In some experiments, we also used a mutant of
group A strain, Senegal 1/99, which expressed fHbp ID5 in
variant group 1, and had been engineered to have increased
expression of fHbp [24]. For measurement of inhibition of fH
binding to the bacterial surface, ,10
7 bacterial cells/ml were
incubated with 50 or 2 mg/ml of anti-fHbp mAb for 30 min at
room temperature, followed by the addition of ,90 mg/ml of
human fH. The source of fH was heat-inactivated (30 min at
56uC) 20% human serum that had been depleted of IgG as
previously described [43]. Bound fH was detected by a sheep
polyclonal antiserum to fH (LifeSpan BioSciences) followed by
washing and incubation with a donkey anti-sheep IgG antibody
(Invitrogen) conjugated with Alexa Fluor 488.
Serum bactericidal assay
Complement-mediated bactericidal activity was measured as
previously described [39,43] using group B strain H44/76. The
bacterial cells were grown to mid-log phase in broth culture,
harvested by centrifugation and washed and resuspended in buffer
as described elsewhere [27]. Immediately before performing the
assay, the anti-fHbp mAbs were centrifuged for 2 h at 100,0006g
to remove possible aggregates. The 40 ml bactericidal reaction
mixture contained 1 to 100 mg/ml of mAb, ,300–400 CFU of
bacteria and 20% complement. The complement source was
either human or infant rabbit serum. The human complement was
serum from a healthy adult with normal total hemolytic
complement activity and no detectable serum bactericidal
antibodies against the test strain. To eliminate non-bactericidal
IgG antibodies that might augment or inhibit the activity of the
test mAbs, the human serum was depleted of IgG using a protein
Figure 6. Structural model of fH-fHbp complex. fH fragment is
shown in gray. The amino-terminal domain of fHbp is shown in light
blue, while the carboxy-terminal domain is shown in light green. Panel
A. Alanine substitutions for arginine at residue 204 (R204A) or for lysine
at position 143 (K143A) decreased or eliminated JAR 1 binding. His
substitution for Arg at position 204 (R204H) did not affect JAR 1 binding
(See Figure 5). Panel B. Residues shown previously by NMR to be part
of the mAb502 binding site [29]. In addition, we found that alanine or
histidine substitutions for arginine at residue 204 (R204A or R204H)
eliminated binding of mAb502, and an alanine substitution for aspartic
acid at residue 142 (D142A) decreased binding (See Figure 3). The figure
was constructed with PyMol (http://www.pymol.org).
doi:10.1371/journal.pone.0034272.g006












JAR 1 ID 1 IgG3 Arg204 Welsh et al [22] JQ085280; JQ085281
mAb502 ID 1 IgG2a Arg204** Giuliani et al, [28]
and Scarselli et al [29]
EU835941; EU835942
Control mAbs
JAR 5 ID 1 IgG2b Gly121 and Lys122 Welsh et al [22]
and Beernink et al [32]
JF715927; JF715926
JAR 13 ID 77 IgG2a Ser216 Beernink et al [32] Not done
JAR 65 Mutant ID 1 with R41S IgG1 Unknown Unpublished Not done
All but one of the hybridomas were from CD-1 mice. The exception, JAR 65, was from a human fH transgenic BALB/c mouse [43].
*fHbp mutants with amino acid substitutions at these positions lost (knocked-out) or gained (knocked-in) mAb binding [32,39].
**The amide signals of Gly148, Arg149, and Ala174 showed chemical shifts by NMR upon binding with fHbp [29].
doi:10.1371/journal.pone.0034272.t002
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which was performed as previously described [43]. The rabbit
complement was serum pooled from normal rabbits 3–4 weeks old
(Cedarlane Labs). Bactericidal activity (BC50%) was defined as the
anti-fHbp mAb concentration that resulted in a 50% decrease in
CFU/ml after 60-min incubation in the reaction mixture
compared with CFU/ml in negative control wells at time zero.
Epitope mapping using yeast display
Randomly mutated libraries of fHbp ID 1 were generated by
error-prone PCR. MnCl2 concentrations were titrated, and
conditions selected such that the average number of amino acid
substitutions per molecule ranged from 1 to 3. Mutated fHbp ID 1
proteins were displayed on the surface of yeast as Aga2 fusion
proteins as described by Boder and Wittrup [45,46]. The vector
pYD1 and the host yeast strain EBY100 were purchased from
Invitrogen (Carlsbad, CA). The mutagenic PCR products were
ligated into pUC18, expanded in E. coli, excised, and inserted into
pYD1. Yeast were transformed with the plasmid library, expanded
overnight at 30uC, transferred into Galactose-containing YNB
medium (Yeast Nitrogen Base w/o amino acids; Difco) to induce
recombinant protein expression, and incubated for 48 hrs at 20uC.
Bulk yeast cultures were simultaneously stained with anti-fHbp
mAb JAR 1 conjugated to DyLight 649 and a non-competing anti-
fHbp mAb, JAR 5, which was conjugated to DyLight 488. The
yeast cells were sorted to select clones that had lost the ability to
bind JAR 1 but retained binding to JAR 5, which verified surface
expression of the fHbp construct. Single clones were re-grown,
their binding profiles verified, and the sequence of the fHbp insert
they contained was determined to identify amino acid substitutions
that resulted in the loss of the JAR 1 epitope. A total of 55
JAR12/JAR5+ yeast clones were analyzed and the sequences of
their inserts aligned to identify altered residues that led to the loss
of JAR 1 binding.
Construction of site-specific mutants
In order to determine whether the residues identified by the
yeast display studies affected JAR 1 epitope expression, we used
site directed mutagenesis to individually replace each of the
residues by alanine. The sequences of the mutagenic oligonucleotides
were: D142A_fwd, GCCAAGCTTCCCGAAGGCG; D142A_
rev, AAAAGATGTATGTTCGCCCGC; K143A_fwd, GCC-
CTTCCCGAAGGCGG; K143A_rev, GTCAAAAGATGTAT-
GTTCGCCCG; R204A_fwd, GCCCATGCCGTCATCAGCG;
R204A_rev, TTTTCCATCCGGCTTGATATC; R204H_fwd, AG-
CCGGATGGAAAACACCATGCCGTCATCAG; R204H_rev,
CTGATGACGGCATGGTGTTTTCCATCCGGCT. The oligo-
nucleotides were phosphorylated with T4 polynucleotide kinase (New
England Biolabs) prior to PCR amplification. Mutants were
constructed using the Phusion Site-Directed Mutagenesis Kit (Thermo
Scientific) using the manufacturer’s protocols. The mutagenesis
reactions were transformed into chemically competent E. coli DH5a
(Invitrogen) and independent mutant clones were verified by DNA
sequencing.
Purification of recombinant fHbp
The wild-type fHbp amino acid sequence variants and site-
specific mutant proteins were expressed from the T7 promotor
using the E. coli plasmid pET21b (Novagen) as described
previously [19,32]. The recombinant proteins were purified by
immobilized metal ion chromatography using Ni-NTA agarose
(Qiagen) as described previously. Purified fHbps were dialyzed
against PBS, sterilized by filtration (Millex 0.22 mm; Millipore),
and stored at 4uC prior to use. The protein concentrations were
determined by UV absorbance (Nanodrop 1000) based on the
extinction coefficient calculated from the amino acid sequence
[47].
Supporting Information
Figure S1 Representative alignments of 13 amino acid
sequences inferred from fHbp gene inserts encoding
mature proteins of representative fHbp mutants in JAR
1-negative/JAR 5-positive yeast clones. The sequences were
selected based on those encoding 1 to 3 amino acid substitutions
from that of wild-type fHbp ID 1 (gene encoding fHbp from strain
MC58 [22].
(DOC)
Figure S2 Binding of fH to mutants of fHbp ID 1 as
measured by ELISA. Panel A. Binding of fH. The D142A,
K433A, R204 and R204H mutations, which affected binding of
JAR 1 and/or mAb502, did not affect fH binding. The R41S
mutant of fHbp ID (white circles), which was known not to bind
fH, served as a negative control [43]. (Panel B. Binding of anti-
fHbp mAb, JAR 5. Symbols same as in Panel A. Wells were coated
with 2 mg/ml of wild-type or mutant fHbp.
(DOC)
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